With a one year PEG ratio of 1,000.7, Supernus Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 95.19% of US stocks.
Supernus Pharmaceuticals Inc's stock had its IPO on May 1, 2012, making it an older stock than 28.78% of US equities in our set.
With a price/earnings ratio of 12.19, Supernus Pharmaceuticals Inc P/E ratio is greater than that of about merely 23.98% of stocks in our set with positive earnings.
Stocks with similar financial metrics, market capitalization, and price volatility to Supernus Pharmaceuticals Inc are CRNT, ONDK, ENVA, SGH, and PRGS.
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.
SUPN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for SUPN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Supernus Pharmaceuticals Inc ranked in the 92th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 2561% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Supernus Pharmaceuticals Inc, consider:
The compound growth rate in the free cash flow of Supernus Pharmaceuticals Inc over the past 4.66 years is 0.87%; that's higher than 92.39% of free cash flow generating stocks in the Healthcare sector.
Supernus Pharmaceuticals Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 15.04% of tickers in our DCF set.
SUPN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than only 15.04% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
EGRX, QHC, THC, PTN, and LCI can be thought of as valuation peers to SUPN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.